Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NEN

NANot yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

September 1, 2027

Study Completion Date

September 1, 2027

Conditions

Hepatocellular Carcinoma (HCC)Intrahepatic Cholangiocarcinoma (Icc)Neuroendocrine Tumors

Interventions

RADIATION

89Zr-TLX250 PET/CT

Patients will receive 89Zr-TLX250 for detection of CAIX-expressing tumor by PET imaging.

Trial Locations (2)

CHU de Nantes, Nantes

AP-HP - Site de Beaujon, Paris

All Listed Sponsors

lead

Nantes University Hospital

OTHER

NCT06735560 - Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NEN | Biotech Hunter | Biotech Hunter